Cancer test developer VolitionRx (NYSE:VNRX) revealed that chief executive Cameron Reynolds will be at two conferences this month (November) to discuss the business's progress.
They are the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum in New York on Thursday, November 19 and the Biotech Capital Conference in London on Monday, November 23.
Reynolds will outline the group's business milestones, plans and commercialisation strategy for its NuQ blood-based tests for colorectal cancer (CRC).
Additionally, he will discuss recent clinical developments, including results from a 4,800-subject cancer trial that demonstrated the company's NuQ test accurately detected 95% of pancreatic cancers – the second type of cancer for which VolitionRx currently expects to bring a NuQ panel test to market, following CRC.